Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape
about
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignComplexes of neutralizing and non-neutralizing affinity matured Fabs with a mimetic of the internal trimeric coiled-coil of HIV-1 gp41Hepatitis C Virus E2 Envelope Glycoprotein Core StructureDiscrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralizationCapitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designA Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal AntibodiesThe core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigsBroadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearanceA Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.Prediction of linear B-cell epitopes of hepatitis C virus for vaccine developmentApproaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffoldingMonoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable RegionRational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding SiteDelineation of autoantibody repertoire through differential proteogenomics in hepatitis C virus-induced cryoglobulinemia.Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.CD81 and hepatitis C virus (HCV) infection.Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzeeStructural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.The past, present and future of neutralizing antibodies for hepatitis C virus.Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies.HCV E2 core structures and mAbs: something is still missing.A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.Viral evasion and challenges of hepatitis C virus vaccine development.The dynamic properties of the Hepatitis C Virus E2 envelope protein unraveled by molecular dynamics.Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope.Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice.Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.Computational Modeling of Hepatitis C Virus Envelope Glycoprotein Structure and Recognition.The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein.Conformational Flexibility in the CD81-Binding Site of the Hepatitis C Virus Glycoprotein E2.
P2860
Q26801759-82ADB6DA-1240-4B87-BC8A-2A0E6D9E886DQ27303525-45EAE083-F7CC-4F8B-B247-9B1A4250DBCBQ27680704-435CF45E-2EC5-4C2E-9CD5-4208BB5E0103Q27684579-55C97C90-9D97-4A75-8463-A036BAABDA4AQ30374314-43D48EFE-91BC-4B7E-895E-FEEAFFB3FC1FQ30383939-9714AA29-2815-489A-B3FD-67ECA89872B4Q33612608-D6D8E23A-3F67-46FC-A26A-BC119157AA5DQ33631104-C744E3D3-3A50-4DB6-AFD3-D6B2E8A9513FQ33648339-24034C43-8A9A-4ECD-8236-1547C4BF716BQ33691856-8C142972-6A26-440F-BD5A-6F9A3CD03B89Q34047477-371B7072-5B14-4C9F-A83D-32E48C9E3CCBQ34262165-F89AC53E-FBBF-478A-8D35-F62C0DD9D5E2Q35242585-7FB0084F-74F9-4AAB-B53B-52C6659B398EQ35872361-FC6E0BC6-F4D0-4C43-9F8B-408DD9FE1B23Q35942829-31D8EDCE-C593-45C8-BD36-80E3CF2C2D82Q36334312-AC052E11-B375-49DD-866D-EC2EEF937483Q36590540-63B8C396-8B6A-43DB-9D9A-C51CA70B427EQ37086915-49202061-CC2B-4C21-B880-120FE57C34A4Q37417839-557457E3-DEB6-4CC6-B34C-AA37ED8AB406Q37611819-7A53E361-2F3A-46A0-B15D-262A2BAE50CDQ37713524-E919B2FB-C629-4071-8E3F-A7C955B8770FQ38128299-A02B5493-AB40-4B48-9D4B-EED67F07C765Q38192357-8B6F8966-679D-437A-BD3A-735EF0AEE7C3Q38234934-54B40FE9-2040-4738-A82E-5B37E10518AEQ38244787-38B04FD4-3B72-41A4-A947-5A7C32E6D625Q38262106-B4884B11-DB7A-4879-B0CD-F5A3D959D85AQ38765582-4EC96259-8E3F-43F9-AF26-F4E566D4E7B3Q38856649-956BA79D-761C-4140-8E22-335B1F1AB3A9Q38961608-A9CBD228-5625-4EBC-8173-30F4229444B6Q39923648-29B2DB05-DB5A-46C1-806C-B0065FAB6394Q40088796-C917C1AE-EF4A-4A40-B757-0195507FDA54Q40480101-89478C60-1F3E-42D1-B195-6B0C28904864Q40634075-66E0222B-6574-4418-B38B-C209F333B6D3Q41619358-A45F31D7-D866-4224-AE28-607B4B6350F1Q47236942-2AF75DD4-EBBE-49DF-97FA-8E632C910389Q47238536-3295C1A0-343D-4525-8BC7-68787EADC6D4Q47548062-CFF511DE-417F-4DE1-BFF9-9A814133DD00Q55003572-A88015E0-3887-4A1A-901E-1151BF4F6927Q55299977-39DE4C29-434D-4237-B8EC-6D6D781E525DQ55383950-1D6AEE08-01B4-4539-BCFC-38CE6F25B074
P2860
Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Structural Basis of HCV Neutra ...... to Viral Neutralization Escape
@ast
Structural Basis of HCV Neutra ...... to Viral Neutralization Escape
@en
Structural Basis of HCV Neutra ...... to Viral Neutralization Escape
@nl
type
label
Structural Basis of HCV Neutra ...... to Viral Neutralization Escape
@ast
Structural Basis of HCV Neutra ...... to Viral Neutralization Escape
@en
Structural Basis of HCV Neutra ...... to Viral Neutralization Escape
@nl
prefLabel
Structural Basis of HCV Neutra ...... to Viral Neutralization Escape
@ast
Structural Basis of HCV Neutra ...... to Viral Neutralization Escape
@en
Structural Basis of HCV Neutra ...... to Viral Neutralization Escape
@nl
P2093
P2860
P3181
P1433
P1476
Structural Basis of HCV Neutra ...... to Viral Neutralization Escape
@en
P2093
Annalisa Meola
Laurence Damier-Piolle
Steven K H Foung
Thomas Krey
Zhen-Yong Keck
P2860
P304
P3181
P356
10.1371/JOURNAL.PPAT.1003364
P50
P577
2013-01-01T00:00:00Z